%0 Journal Article
%T The antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110¦Ã catalytic subunit of PI3K¦Ã
%A HUANG
%A SHUAISHUAI
%A REN
%A YU
%A WANG
%A PING
%A WANG
%A XUE
%A WENG
%A GOUBIN
%A XIN
%A XIA
%J -
%D 2019
%R 10.2478/acph-2019-0004
%X Sa£¿etak Umbelliferone exhibits extensive pharmacological activity, including anti-immunomodulatory, anti-inflammatory and antigenotoxicity activities. However, its antitumor properties still remain unclear in human renal cell carcinoma (RCC) cells. Our results have revealed that treatment of human RCC cells (786-O, OS-RC-2, and ACHN) with umbelliferone reduced cell proliferation in a concentration-dependent manner and induced dose-dependent apoptotic events. In addition, cell cycle analysis determined that umbelliferone treatment induced cell cycle arrest in the G1 phase in a dose-dependent manner. Furthermore, western blotting analysis showed a dose-dependent decrease in Ki67, MCM2, Bcl-2, CDK2, CyclinE1, CDK4, and CyclinD1 and a dose-dependent increase in Bax in RCC cells cultured with umbelliferone. Similarly, umbelliferone exhibited a dose-dependent reduction of p110¦Ã when using western blotting analyses. Taken together, these results provide an insight into the pharmacology regarding the potential application of umbelliferone, which contributes to cell death by decreasing p110¦Ã protein expression
%K umbelliferone
%K renal cell carcinoma
%K p110¦Ã
%K anticancer activity
%U https://hrcak.srce.hr/index.php?show=clanak&id_clanak_jezik=303673